The FDA announced on Feb. 27, 2025, that Tandem Diabetes Care, Inc. is recalling t:slim X2 Insulin Pumps with Interoperable Technology due to a software defect that can cause inaccurate insulin delivery. The agency said the issue may lead to severe hypoglycemia or hyperglycemia.
How to tell if you have it
- Brand: Tandem
- Product: t:slim X2 Insulin Pump with Interoperable Technology
- Software version: 7.9
- UDI: 00389152407012
- Units affected: 63
The hazard
A software defect in Version 7.9 of the pump software for Tandem t:slim X2 and Tandem Mobi pumps, when used with Control IQ+ technology, will cause the pump to incorrectly interpolate glucose trends when the Estimated Glucose Value (EGV) is above 255 mg/dL at the start or end of a gap in data collection due to a lapse in connection from a paired continuous glucose monitor (CGM) sensor. This can lead to under-delivery or over-delivery of insulin based on inaccurate result leading to severe cases of hypoglycemia or hyperglycemia.
Context
GovInfoNow's records show Tandem Diabetes Care, Inc. has 10 other recalls on record since April 23, 2018. Other recent recalls of similar products include Medtronic MiniMed 780G Insulin Pump Recall: Software Error Causes Insulin Stoppage (May 27, 2026), Medtronic Paradigm Insulin Pumps Recall: Risk of Severe Hypoglycemia or Hyperglycemia (Feb. 13, 2026) and Medtronic MiniMed 780G Insulin Pump Software Version 6.60 Recall: Risk of Insulin Suspension (Nov. 2, 2025). FDA's MAUDE device-report database has received 36 reports naming slim X2 Interoperable since February 2024, with 2 marked serious.